As Documents are published they will be made available below.



We deliver VALUE to our shareholders:

  • Preserve equity when business or financial milestones are in sight,
  • Maintain a stream of late stage products,
  • Faster availability of capital through partnership,
  • Low risk products as being in phase I, II and III,
  • A stream of revenue from milestone and royalties.


INFORMATION ABOUT LATEST DEVELOPMENTS WILL BE PRESENTED HERE WHEN AVAILABLE

Stock Information

STOCK EXCHANGE
Global Health Venture

OTC.BB SYMBOL: GHLV.OB

FILINGS SEC
FILINGS EDGAR ONLINE


FRANKFURT
Click here for
FRANKFURT Trading Chart







XETRA CHART

Projects Highlights

Product GHL901 - Sex

This product is a sublingual version of an existing anti erectile dysfunction druge in lage stage development

Product GHL902 - Addiction

This product is a sublingual version of an existing anti addiction product against a wide range of drug abuse.

Product GHL903 - Obesity

This product is a sublingual version of an appetite lowering drug in early stages of development .

Latest News

Yahoo! Finance: GHLV.OB News
 
GLOBAL HEALTH VENTURES INC. Files SEC form 10-K, Annual Report

 
Global Health Ventures Expects Completion of European Clinical Trials for X-Excite in the Fourth Quarter of 2010

 
Liberty Analytics Co. Initiates Independent Research Coverage on Global Health Ventures, Inc.